Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Stanislava, Schejbalová"'
Autor:
Elzbieta Kompanowska-Jezierska, Zdeňka Vaňourková, Agnieszka Walkowska, Dan Rakušan, Ivana Vaněčková, Zuzana Husková, Martin Opočenský, Věra Čertíková Chábová, Petr Kujal, Petra Škaroupková, Ivan Netuka, Libor Kopkan, Herbert J. Kramer, Zdenka Vernerová, Jan Malý, Stanislava Schejbalová, Janusz Sadowski, Luděk Červenka
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 37:1159-1169
Summary 1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7af4666542af4993941590e68599e987
https://doi.org/10.1111/j.1440-1681.2010.05453.x
https://doi.org/10.1111/j.1440-1681.2010.05453.x
Autor:
Zuzana Husková, Zdenka Vaňourková, Luděk Červenka, Herbert J. Kramer, Ivana Vaněčková, Libor Kopkan, Stanislava Schejbalová
Publikováno v:
Vascular Pharmacology. 47:63-67
The effectiveness of antisense (AS) phosphorothioated oligodeoxynucleotides (AS-ODN) targeted to the angiotensin (ANG) type 1 (AT1) receptor, was studies in Ren-2 transgenic rats (TGR), whose ANG II-dependent hypertension can be attributed to the ins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a6960e77b0e491fd6e9efd0c5fa2d18
https://doi.org/10.1016/j.vph.2007.04.005
https://doi.org/10.1016/j.vph.2007.04.005
Autor:
Ludek Cervenka, Herbert J. Kramer, Stanislava Schejbalová, Zdenka Vanourkova, Libor Kopkan, Ivana Vaneckova, Zuzana Husková
Publikováno v:
Kidney and Blood Pressure Research. 30:38-44
The aim of this study was first to evaluate the effects of persistent or transient blockade of the angiotensin II (ANG II) receptor AT1 on the development of hypertension and end-organ damage in hypertensive Ren-2 transgenic rats (TGR), and second to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8935403d01f0d4a7f9b16c6f2da97ac
https://doi.org/10.1159/000098869
https://doi.org/10.1159/000098869
Autor:
Petr, Kujal, Věra Čertíková, Chábová, Zdenka, Vernerová, Agnieszka, Walkowska, Elzbieta, Kompanowska-Jezierska, Janusz, Sadowski, Zdeňka, Vaňourková, Zuzana, Husková, Martin, Opočenský, Petra, Skaroupková, Stanislava, Schejbalová, Herbert J, Kramer, Dan, Rakušan, Jan, Malý, Ivan, Netuka, Ivana, Vaněčková, Libor, Kopkan, Luděk, Cervenka
Publikováno v:
Clinical and experimental pharmacologyphysiology. 37(12)
1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6ad50cdbdd00def530e6c3e5efdd8358
https://pubmed.ncbi.nlm.nih.gov/20880190
https://pubmed.ncbi.nlm.nih.gov/20880190
Autor:
Ivana, Vanecková, Libor, Kopkan, Zuzana, Husková, Zdenka, Vanourková, Stanislava, Schejbalová, Ludek, Cervenka, Herbert J, Kramer
Publikováno v:
Kidneyblood pressure research. 30(1)
The aim of this study was first to evaluate the effects of persistent or transient blockade of the angiotensin II (ANG II) receptor AT(1) on the development of hypertension and end-organ damage in hypertensive Ren-2 transgenic rats (TGR), and second
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b91ba4d72ba7bb3aefb5085fd4c25a74
https://pubmed.ncbi.nlm.nih.gov/17237618
https://pubmed.ncbi.nlm.nih.gov/17237618
Autor:
Václav Eis, Stanislava Schejbalová, Zdenka Vaňourková, Vladimír Tesař, Věra Čertíková Chábová, Zuzana Husková, John D. Imig, Petra Škaroupková, Herbert J. Kramer, Luděk Červenka, Ivana Vaněčková, Zdena Vernerová, Alexander Kolský, Monika Thumová
Publikováno v:
Vascular pharmacology. 47(2-3)
The aim of the present study was to evaluate the effects of inhibition of cytochrome P-450 (CYP) activity by 1-aminobenzotriazole (ABT) and by CoCl(2), first, on the development of hypertension when treatment was started in young male heterozygous Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ae9f10c2d367a5e51bd4b65bb33b7bd
https://pubmed.ncbi.nlm.nih.gov/17604232
https://pubmed.ncbi.nlm.nih.gov/17604232
Autor:
Luděk Červenka, Zdena Vernerová, Pavel Dvořák, Angela Bäcker, Herbert J. Kramer, Martin Opočenský, Ivana Vaněčková, Stanislava Schejbalová, Václav Eis
Publikováno v:
Vascular pharmacology. 45(3)
Male heterozygous Ren-2 transgenic rats and Hannover Sprague-Dawley rats fed a normal or high-salt diet were either untreated or treated with the nonselective receptor ET(A)/ET(B) receptor blocker bosentan or the selective ET(A) receptor blocker, ABT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ab9edac69c2ba8eac85fdf0da6e2c9d
https://pubmed.ncbi.nlm.nih.gov/16807127
https://pubmed.ncbi.nlm.nih.gov/16807127